Clinical Trial

Southeast Netherlands Advanced Metastatic Breast Cancer Registry

Study acronym: SONABRE
Recruiting
View on ClinicalTrials.gov →
Summary
The Southeast Netherlands Advanced Breast Cancer (SONABRE) Registry is a real life multi-center study. The registry aims to include all patients diagnosed with advanced breast cancer as of 2007 in 11 hospitals in the Netherlands. Data on patient, tumor and treatment characteristics are collected retrospectively from electronic medical files by trained registry clerks.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2018-07-02; most recent amendment 2024-07-19.
Trial Details
NCT Number NCT03577197
Lead Sponsor Academisch Ziekenhuis Maastricht
Collaborators: Novartis, Pfizer, Roche Pharma AG, Eli Lilly and Company, ZonMw: The Netherlands Organisation for Health Research and Development, Eisai Inc., Daiichi Sankyo, AstraZeneca, Gilead Sciences
Conditions Advanced Breast Cancer, Metastatic Breast Cancer
Enrollment 7,000 participants
Start Date 2007-01-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-23